Literature DB >> 11698047

Nitric oxide and mechanisms of redox signalling: matrix and matrix-metabolizing enzymes as prime nitric oxide targets.

J Pfeilschifter1, W Eberhardt, A Huwiler.   

Abstract

One of the greatest biomedical breakthroughs of the twentieth century was the discovery of endothelium-derived relaxing factor and its identification as nitric oxide (NO). NO has received special attention ever since: besides its potent vasodilatory and vasoprotective effects, NO was identified as a key player in innate immunity and was found to act as an unconventional type of neurotransmitter. This article focuses on mechanisms of NO signalling that form the basis of functional cell responses to accommodate changes in the cellular microenvironment. Redox-based regulation of signal transduction and, on a more long-term scale, changes in gene expression will be exemplified by NO-modulation of matrix components and matrix-metabolizing enzymes. It seems to be a safe bet that ongoing analyses of NO signalling and gene expression will provide a wealth of promising therapeutic targets in human diseases.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11698047     DOI: 10.1016/s0014-2999(01)01326-7

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  10 in total

1.  Inducible nitric oxide synthase inhibition reverses pulmonary arterial dysfunction in lung transplantation.

Authors:  Jing-Xiang Wu; Hong-Wei Zhu; Xu Chen; Jiong-Lin Wei; Xiao-Feng Zhang; Mei-Ying Xu
Journal:  Inflamm Res       Date:  2014-04-24       Impact factor: 4.575

2.  Concomitant reduction of matrix metalloproteinase-2 secretion and intracellular reactive oxygen species following anti-sense inhibition of telomerase activity in PC-3 prostate carcinoma cells.

Authors:  Ahmad Shariftabrizi; Mohammad Reza Khorramizadeh; Farshid Saadat; Kamran Alimoghadam; Farnaz Safavifar; Mohammad Reza Ebrahimkhani
Journal:  Mol Cell Biochem       Date:  2005-05       Impact factor: 3.396

3.  The influence of opioids on matrix metalloproteinase-2 and -9 secretion and mRNA levels in MCF-7 breast cancer cell line.

Authors:  Katarzyna Gach; Janusz Szemraj; Anna Wyrębska; Anna Janecka
Journal:  Mol Biol Rep       Date:  2010-06-20       Impact factor: 2.316

Review 4.  Matrix metalloproteinases in diabetic retinopathy: potential role of MMP-9.

Authors:  Renu A Kowluru; Qing Zhong; Julia M Santos
Journal:  Expert Opin Investig Drugs       Date:  2012-04-23       Impact factor: 6.206

5.  Nitric oxide increases the decay of matrix metalloproteinase 9 mRNA by inhibiting the expression of mRNA-stabilizing factor HuR.

Authors:  El-Sayed Akool; Hartmut Kleinert; Farid M A Hamada; Mohamed H Abdelwahab; Ulrich Förstermann; Josef Pfeilschifter; Wolfgang Eberhardt
Journal:  Mol Cell Biol       Date:  2003-07       Impact factor: 4.272

6.  Oxidative stress and the development of diabetic retinopathy: contributory role of matrix metalloproteinase-2.

Authors:  Renu A Kowluru; Mamta Kanwar
Journal:  Free Radic Biol Med       Date:  2009-04-05       Impact factor: 7.376

7.  Interleukin-1beta inhibits ATP-induced protein kinase B activation in renal mesangial cells by two different mechanisms: the involvement of nitric oxide and ceramide.

Authors:  Waltraud Rölz; Cuiyan Xin; Shuyu Ren; Josef Pfeilschifter; Andrea Huwiler
Journal:  Br J Pharmacol       Date:  2003-02       Impact factor: 8.739

Review 8.  Molecular mechanisms in endothelial regulation of cardiac function.

Authors:  Leena Kuruvilla; Chandrasekharan Cheranellore Kartha
Journal:  Mol Cell Biochem       Date:  2003-11       Impact factor: 3.396

9.  Modulation of fibrosis in systemic sclerosis by nitric oxide and antioxidants.

Authors:  Audrey Dooley; K Richard Bruckdorfer; David J Abraham
Journal:  Cardiol Res Pract       Date:  2011-10-31       Impact factor: 1.866

10.  Effect of Nitric Oxide on the Expression of Matrix Metalloproteinase and Its Association with Migration of Cultured Trabecular Meshwork Cells.

Authors:  Jae Woo Kim
Journal:  Korean J Ophthalmol       Date:  2016-01-21
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.